|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,805.00 GBX | -1.15% |
|
+0.78% | +34.05% |
| 12-05 | Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns | RE |
| 12-05 | Health Rounds: Shingles vaccine reduces risk of death from dementia, study finds | RE |
| Capitalization | 72.45B 96.52B 82.97B 77.73B 134B 8,687B 146B 909B 351B 4,103B 362B 355B 15,001B | P/E ratio 2025 * |
12.9x | P/E ratio 2026 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise value | 86.71B 116B 99.31B 93.03B 160B 10,398B 174B 1,088B 420B 4,911B 434B 424B 17,956B | EV / Sales 2025 * |
2.67x | EV / Sales 2026 * | 2.46x |
| Free-Float |
94.52% | Yield 2025 * |
3.6% | Yield 2026 * | 3.87% |
Last Transcript: GSK plc
| 1 day | -1.15% | ||
| 1 week | +0.78% | ||
| Current month | +0.78% | ||
| 1 month | +0.95% | ||
| 3 months | +22.29% | ||
| 6 months | +19.38% | ||
| Current year | +34.05% |
| 1 week | 1,781 |  | 1,853.5 |
| 1 month | 1,753 | | 1,853.5 |
| Current year | 1,242.5 | | 1,853.5 |
| 1 year | 1,242.5 | | 1,853.5 |
| 3 years | 1,242.5 | | 1,853.5 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 56 | 2017-03-31 |
Julie Brown
DFI | Director of Finance/CFO | 63 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
BRD | Director/Board Member | 56 | 2016-12-31 |
Hal Barron
BRD | Director/Board Member | 63 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.15% | 26 M€ | +11.73% | - |
| 2.97% | 62 M€ | +15.22% | - |
| 2.51% | 8 M€ | +24.12% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.15% | +0.78% | +34.55% | +26.92% | 96.52B | |
| -0.41% | -6.06% | +22.37% | +173.58% | 905B | |
| -0.27% | -2.41% | +35.05% | +12.95% | 487B | |
| -1.15% | -0.71% | +28.33% | +37.90% | 400B | |
| +0.26% | +1.14% | +21.30% | +0.44% | 330B | |
| +0.58% | -2.73% | +28.01% | +20.71% | 281B | |
| +0.19% | +2.49% | +18.48% | +24.80% | 255B | |
| -1.16% | -4.87% | -3.70% | -9.35% | 248B | |
| +1.24% | -2.33% | -59.84% | -31.25% | 214B | |
| -3.02% | -4.51% | +20.25% | +15.79% | 178B | |
| Average | -0.30% | -1.92% | +14.48% | +27.25% | 339.3B | |
| Weighted average by Cap. | -0.12% | -2.69% | +18.10% | +55.16% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 32.5B 43.31B 37.23B 34.87B 60.03B 3,897B 65.3B 408B 157B 1,841B 163B 159B 6,730B | 34.26B 45.65B 39.24B 36.76B 63.28B 4,108B 68.83B 430B 166B 1,940B 171B 168B 7,094B |
| Net income | 5.63B 7.5B 6.45B 6.04B 10.4B 675B 11.31B 70.64B 27.27B 319B 28.15B 27.55B 1,166B | 6.35B 8.46B 7.27B 6.81B 11.72B 761B 12.75B 79.65B 30.76B 359B 31.74B 31.06B 1,314B |
| Net Debt | 14.27B 19.01B 16.34B 15.31B 26.35B 1,711B 28.67B 179B 69.14B 808B 71.35B 69.83B 2,955B | 11.78B 15.69B 13.49B 12.64B 21.76B 1,412B 23.66B 148B 57.07B 667B 58.9B 57.64B 2,439B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 1,805.00 p | -1.15% | 4,275,805 |
| 25-12-04 | 1,826.00 p | -0.38% | 9,014,389 |
| 25-12-03 | 1,833.00 p | +0.77% | 9,069,137 |
| 25-12-02 | 1,819.00 p | +1.06% | 8,474,628 |
| 25-12-01 | 1,800.00 p | +0.50% | 12,683,880 |
Delayed Quote London S.E., December 05, 2025 at 11:35 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition